Interview with Hiro Fukutomi, Managing Director, Takeda UK
What is the importance of the UK operations for Takeda worldwide? Our UK operation was established in 1997 and is relatively younger than other affiliates in Europe such as Takeda…
Address: 1 Royal College St ,London, Greater London NW1 0SB, UK
Tel: +44(0) 20 7691 4906
Web: http://www.xeneticbio.com/
Xenetic is a leading UK based biopharmaceutical company providing leading edge expertise in the development of a whole new generation of drugs and vaccines.
Working with some of the largest pharmaceutical organisations in the world, Xenetic provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas.
We are also actively developing our own pipeline of next generation biotherapeutics based on our proprietary PolyXen andImuXen platform technologies.
Xenetic’s biopharmaceutical pipeline contains a range of product candidates which are currently under development either in-house or with biotechnology and pharmaceutical partners. The products in Xenetic’s pipeline have a multi-billion dollar market potential.
Pipeline products are based on Xenetic’s proprietary drug and vaccine delivery technologies and have been developed to offer improved performance and delivery characteristics. Xenetic’s unique delivery technologies are also able to create new high-value, differentiated proprietary products from off-patent actives.
Xenetic has established a range of partnerships with major US, European, Russian and Asian biotechnology and pharmaceutical companies to develop new protein therapeutics and vaccines. Click here to learn more about the work we do with our partners.
What is the importance of the UK operations for Takeda worldwide? Our UK operation was established in 1997 and is relatively younger than other affiliates in Europe such as Takeda…
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
You used to be the Managing Director of Ranbaxy in China. Having moved to a directorship in the UK, what professional challenges do you see in this country that distinguish…
Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just twelve years. If we…
Before joining Bristol-Myers Squibb (BMS), you have spent roughly twenty years with GSK. Can you describe the trajectory of your career and explain what attracted you in BMS? Before joining…
Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed…
Astellas’s European headquarters is based in the UK. What does the UK market represent for the company? Speaking from a global perspective, 60% of Astellas’ business is based in Japan…
This year’s Q1 results for Novo Nordisk were extremely positive with a 23% increase in profit. While this growth was mostly driven by the US and emerging markets, what does…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
Taking a look at a key achievement of the ABPI in recent years, we recognize the role you played in negotiating the revised PPRS that was put in place last…
It are exciting times for the UK, with the public healthcare system undergoing so many changes. The Office of Life Sciences (OLS) and the Therapeutic Capability Clusters are just some…
See our Cookie Privacy Policy Here
